The virus that causes COVID-19 today is not the same as the first sickened people way back in December 2019. Many current variants are partially resistant to some of the antibody-based therapeutics developed based on the original virus. As the pandemic continues, more variants inevitably will arise, and the problem of resistance will only grow.
Researchers at Washington University School of Medicine in St. Louis have identified a highly protective antibody at low doses against a wide range of viral variants. Moreover, the antibody attaches to a part of the virus that differs little across the variants, making it unlikely that resistance will arise at this spot. The findings, available online in the journal Immunity, could be a step toward developing new antibody-based therapies that are less likely to lose their potency as the virus mutates.
‘Current antibodies may work against some but not all variants,’ said senior author Michael Diamond, MD, PhD, the Herbert Gasser, professor of medicine.’The virus will likely continue to evolve and space. Having broadly neutralising, effective antibodies that work individually and can be paired to make new combinations will likely prevent resistance.’
SARS-CoV-2, the virus that causes COVID-19, uses a protein called spike to attach to and invade cells in the body’s respiratory tract. Antibodies that prevent spikes from attaching to cells neutralise the virus and prevent disease. Many variants have acquired mutations in their spike genes that allow them to evade some antibodies generated against the original strain, undermining the effectiveness of antibody-based therapeutics.
To find neutralising antibodies that work against a wide range of variants, the researchers began by immunising mice with a key part of the spike protein known as the receptor-binding domain. Then, they extracted antibody-producing cells and obtained 43 antibodies from them that recognise the receptor-binding domain.
Along with Diamond, the research team included co-first authors Laura VanBlargan, PhD, a staff scientist; Lucas Adams, an MD/PhD student; and Zhuoming Liu, PhD, a staff scientist; as well as co-author Daved Fremont, PhD, a professor of pathology & immunology, of biochemistry & molecular biophysics and molecular microbiology.
The researchers screened the 43 antibodies by measuring how well they prevented the original variant of SARS-CoV-2 from infecting cells in a dish. Nine of the most potent neutralising antibodies were then tested in mice to see whether they could protect animals infected with the original SARS-CoV-2 from disease. Multiple antibodies passed both tests, with varying degrees of potency.
The researchers selected the two most effective antibodies at protecting mice from disease and tested them against a panel of viral variants. The panel comprised viruses with spike proteins representing all four variants of concern (alpha, beta, gamma and delta), two of interest (kappa and iota), and several unnamed variants monitored as potential threats. One antibody, SARS2-38, easily neutralised all the variants.
Moreover, a humanised version of SARS2-38 protected mice against disease caused by two variants: kappa and a virus containing the spike protein from the beta variant. The researchers noted that the beta variant is notoriously resistant to antibodies, so its inability to resist SARS2-38 is remarkable.
Further experiments pinpointed the precise spot on the spike protein recognised by the antibody and identified two mutations at that spot that could, in principle, prevent the antibody from working. These mutations are vanishingly rare in the real world, however. The researchers searched a nearly 800,000 SARS-CoV-2 sequences database and found escape mutations in only 0.04% of them.
‘This antibody is both highly neutralising (meaning it works very well at low concentrations) and broadly neutralising (meaning it works against all variants),’ said Diamond, who is also a professor of molecular microbiology and pathology & immunology. ‘That’s an unusual and very desirable combination for an antibody.’
‘Also, it binds to a unique spot on the spike protein that isn’t targeted by other antibodies under development. That’s great for combination therapy. We could start thinking about combining this antibody with another one that binds somewhere else to create a combination therapy that would be very difficult for the virus to resist.’